Combining the power of nature and genomics to create new medicines

DemurisTM has a large portfolio of drug projects and state-of-the-art platform technologies in natural product discovery, design and production

The rise in drug resistant pathogens is causing serious health concerns and an increasing economic burden. There is a growing demand for new agents to treat these evolving diseases. Demuris is developing a suite of new antibiotic compounds active in key areas of unmet medical need.

The starting points for Demuris’ portfolio of new drug project portfolio lies in a unique collection of Actinomycete bacteria. These organisms specialise in making natural product (NP) compounds with powerful biological activities that kill or manipulate the behaviour of surrounding organisms, including bacteria, fungi, plants and animals.

Demuris is also developing advanced molecular biology and synthetic biology methods to identify new NPs, and manipulate them to make better drug-like molecules and at much higher yields.

Demuris can also offer its technology platform as a service for academics and companies wishing to discover and develop new drugs.

... only a fraction of the natural products that these bacteria are capable of making has been screened


Demuris Receives SBRI Innovate UK Grant to Identify Novel Treatments for Gram Negative Infections

New antibiotics are urgently needed to combat the rise of Multi-Drug Resistance (MDR), and the most pressing are treatments for MDR-Gram-negative pathogens. The World Health Organization (WHO) considers it critical to find new therapies to overcome Gram-negative resistance, particularly against carbapenem-resistant pathogens because they are resistant to all or nearly all of the antibiotics available today. The United States Centers for Disease Control and Prevention estimates that 2 million Americans acquire serious infections caused by antibiotic-resistant bacteria each year, and 23,000 of them die as a result.

This grant will allow Demuris to conduct whole genome DNA sequencing of a large number of bacteria that Demuris have previously identified as producers of antibiotics against Gram negative pathogens. Although many of these organisms will produce known molecules, Demuris will then use its bioinformatic tools to rapidly eliminate these and focus drug development activities on organisms with the potential to be making completely new antibiotics.

Demuris has developed proprietary technologies to enhance the discovery and optimization of bioactive compounds from natural sources. This includes its Turbolibrary platform for generating vast numbers of novel, bioactive compounds from previously silent biosynthetic gene clusters. This system is being applied on Demuris’ internal collection of rare taxonomically-sifted actinomycete bacteria obtained from all over the world and from a vast array of diverse environments.

Demuris has also developed the 3G Platform of advanced genomics, informatics and synthetic biology technologies which enable fast and cost-effective transition from Hit to Drug Lead by rapid dereplication/prioritization of Leads, elaboration of natural and synthetic analogues, and rapid and efficient compound production.

Demuris is developing lead compounds to address major disease area problems in oncology, mitochondrial disease and drug resistant infectious diseases, in partnership with various collaborators and partners.

Demuris Limited
Newcastle Biomedicine Bio-Incubators,
Faculty of Medical Sciences, Framlington Place,
Newcastle upon Tyne, NE2 4HH, UK

Tel: +44 (0)191 223 5608
Please see note on Contact page

Fax: +44 (0)191 223 5609

Demuris Limited is registered in England, company number: 06255507

Demuris Limited 2015